Citigroup’s Lucid Diagnostics LUCD Stock Holding History

Citigroup’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.08K	Buy	4,417 +2,377	+117%	+$3.02K	﹤0.01%	5262
2025 Q4	$2.22K	Sell	2,040 -1,933	-49%	-$2.16K	﹤0.01%	5440
2025 Q3	$4.01K	Sell	3,973 -19,834	-83%	-$21.7K	﹤0.01%	5295
2025 Q2	$27.4K	Buy	+23,807	New	+$30.7K	﹤0.01%	5006
2022 Q3	–	Sell	-48	Closed	–	–	6119
2022 Q2	$0	Sell	48 -650	-93%	-$1.44K	﹤0.01%	6478
2022 Q1	$2K	Sell	698 -1,653	-70%	-$6.04K	﹤0.01%	6072
2021 Q4	$13K	Buy	+2,351	New	+$19.1K	﹤0.01%	5509

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Citigroup's LUCD Position: Q1 2026 in Review

Citigroup increased its Lucid Diagnostics (LUCD) stake by 117% in Q1 2026, buying an estimated $3.02K and bringing the position to 4,417 shares worth $5.08K. The position accounts for ﹤0.01% of the portfolio, ranked #5262.

Citigroup first reported a position in LUCD in Q4 2021 and has held it in 7 quarters since. The position peaked at $27.4K in Q2 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Citigroup held 4,417 shares of Lucid Diagnostics worth $5.08K as of Q1 2026.
Citigroup bought 2,377 Lucid Diagnostics shares in Q1 2026, an estimated $3.02K.
Lucid Diagnostics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5262 holding.
Citigroup first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 7 quarters since.
Citigroup's Lucid Diagnostics position peaked at $27.4K in Q2 2025.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.